FRM
EPZM

Fox Run Management’s Epizyme, Inc EPZM Stock Holding History

Fox Run Management’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-11,717
Closed -$145K – 683
2019
Q1 		$145K Buy
+11,717
New +$131K 0.08% 411
2018
Q3 		– Sell
-31,428
Closed -$426K – 890
2018
Q2 		$426K Buy
31,428
+10,337
+49% +$161K 0.14% 308
2018
Q1 		$374K Buy
21,091
+1,816
+9% +$30.7K 0.09% 421
2017
Q4 		$242K Buy
19,275
+7,575
+65% +$110K 0.07% 526
2017
Q3 		$223K Buy
+11,700
New +$179K 0.06% 580
2016
Q2 		– Sell
-14,900
Closed -$181K – 713
2016
Q1 		$181K Buy
+14,900
New +$151K 0.12% 351

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Fox Run Management's EPZM Position: Q2 2019 in Review

Fox Run Management sold out of Epizyme, Inc (EPZM) in Q2 2019, closing a stake of 11,717 shares — an estimated $145K sold.

Fox Run Management first reported a position in EPZM in Q1 2016 and held it in 6 quarters. The position peaked at $426K in Q2 2018. 134 funds tracked by Wall St. Rank hold EPZM as of Q2 2019.

  • Fox Run Management reported no remaining Epizyme, Inc position as of Q2 2019 after selling out during the quarter.
  • Fox Run Management sold 11,717 Epizyme, Inc shares in Q2 2019, an estimated $145K.
  • Fox Run Management first reported a position in Epizyme, Inc in Q1 2016 and held it in 6 quarters.
  • Fox Run Management's Epizyme, Inc position peaked at $426K in Q2 2018.
  • 134 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2019.

Based on Fox Run Management's 13F filing for Q2 2019, filed 17 Jul 2019.